We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Maccura Biotechology Co.,Ltd.

Maccura is an integrated in vitro diagnosis company offering a wide range of products in the areas of clinical bioche... read more Featured Products: More products

Download Mobile App





Diazyme Partners with Maccura Biotechnology to Launch FDA EUA Approved SARS-CoV-2 RT-PCR Diagnostics Test

By LabMedica International staff writers
Posted on 03 Aug 2020
Print article
Image: SARS-CoV-2 RT-PCR diagnostics test (Photo courtesy of Maccura Biotechnology)
Image: SARS-CoV-2 RT-PCR diagnostics test (Photo courtesy of Maccura Biotechnology)
Diazyme Laboratories, Inc. (Poway, CA, USA) has entered into a partnership with Maccura Biotechnology (Sichuan, China) for the launch of a FDA EUA approved SARS-COV-2 RT-PCR diagnostics test.

Maccura’s SARS-CoV-2 Fluorescent PCR Kit is designed for triple-targets and is better at preventing the missed detection of SARS-CoV-2. At the same time, internal standards are added to prevent false negative test results. Clinical tests have shown that the kit has good performance, high sensitivity and specificity. The test also takes a relatively short time and can complete 96 tests within two hours.

"Here at Diazyme, we continue to address gaps in testing during the COVID-19 public health emergency. The SARS-CoV-2 Fluorescent PCR Kit- Maccura Biotechnology (USA) LLC is a RT-PCR test intended for the qualitative detection of SARS-CoV-2 viral nucleic acids in upper respiratory specimens (e.g., oropharyngeal swabs, nasopharyngeal swabs, nasal swabs, and mid-turbinate swabs) from individuals suspected of COVID-19. The demand for molecular diagnostic tests continue to outpace availability and wait times are getting too long to be meaningful in quarantine situations. We are pleased to announce our partnership with Maccura, bringing more test capacity to clinical laboratories", said Dr. Chong Yuan, Managing Director of Diazyme Laboratories, Inc.

"Maccura Biotechnology (USA) LLC is pleased to enter into a partnership with Diazyme Laboratories, Inc. providing additional testing capacity during the public health emergency in the USA. We have a long business relationship with Diazyme and continue to work together in many areas globally," said Jinson Xu, the General Manager of Maccura Biotechnology (USA) LLC.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.